Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy
- PMID: 17292047
- DOI: 10.1016/j.tcm.2006.12.002
Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy
Abstract
Mutations that disrupt the dystrophin glycoprotein complex lead to plasma membrane instability of cardiomyocytes and skeletal muscle myofibers. Instability of the plasma membrane leads to degeneration largely due to activation of a necrotic process in these disorders. In response to ongoing degeneration, skeletal muscle exhibits robust regeneration while in cardiac muscle regeneration is not obvious. The dystrophin complex is concentrated along the plasma membrane in costameric structures that correspond to the Z bands of sarcomeres, thus positioning the dystrophin complex to transmit force between the sarcomere and the plasma membrane to the extracellular matrix. Although it is apparent that this position is important for perpendicular force transmission, it is clear that the dystrophin complex also fulfills signaling roles. Nitric oxide synthase and stress-induced signaling cascades are activated to participate in protection but may also contribute to pathology.
Similar articles
-
Sarcoglycans in muscular dystrophy.Microsc Res Tech. 2000 Feb 1-15;48(3-4):167-80. doi: 10.1002/(SICI)1097-0029(20000201/15)48:3/4<167::AID-JEMT5>3.0.CO;2-T. Microsc Res Tech. 2000. PMID: 10679964 Review.
-
The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma.Circ Res. 2004 Apr 30;94(8):1023-31. doi: 10.1161/01.RES.0000126574.61061.25. Circ Res. 2004. PMID: 15117830 Review.
-
Localization of sarcoglycan, neuronal nitric oxide synthase, beta-dystroglycan, and dystrophin molecules in normal skeletal myofiber: triple immunogold labeling electron microscopy.Microsc Res Tech. 2001 Nov 1;55(3):154-63. doi: 10.1002/jemt.1166. Microsc Res Tech. 2001. PMID: 11747090
-
Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex.J Cell Sci. 2006 Apr 15;119(Pt 8):1537-46. doi: 10.1242/jcs.02857. Epub 2006 Mar 28. J Cell Sci. 2006. PMID: 16569668
-
Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex.J Cell Sci. 2000 Jul;113 ( Pt 14):2535-44. doi: 10.1242/jcs.113.14.2535. J Cell Sci. 2000. PMID: 10862711
Cited by
-
Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.Hum Mol Genet. 2013 Jul 1;22(13):2634-41. doi: 10.1093/hmg/ddt112. Epub 2013 Mar 3. Hum Mol Genet. 2013. PMID: 23459935 Free PMC article.
-
Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy.Clin Sci (Lond). 2014 Jul;127(2):101-9. doi: 10.1042/CS20130602. Clin Sci (Lond). 2014. PMID: 24502705 Free PMC article.
-
Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy.Front Physiol. 2016 Dec 6;7:539. doi: 10.3389/fphys.2016.00539. eCollection 2016. Front Physiol. 2016. PMID: 27999547 Free PMC article.
-
S151A δ-sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice.Eur J Hum Genet. 2014 Jan;22(1):119-25. doi: 10.1038/ejhg.2013.97. Epub 2013 May 22. Eur J Hum Genet. 2014. PMID: 23695275 Free PMC article.
-
Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure.Nat Commun. 2019 Dec 17;10(1):5754. doi: 10.1038/s41467-019-13623-2. Nat Commun. 2019. PMID: 31848331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical